Decreased CSF Aβ1-42 in combination with elevations in tau species and relatively unchanged Aβ1-40 are well-established markers of AD and predict the conversion of mild cognitive impairment (MCI) to AD [28–30]. This evidence concerns the gene MAPT and Alzheimer disease.